
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
PHMR | Madrid | EUR | Delayed | |
PHMR | Derived | EUR | Real-time | |
PHMMF | OTC Markets | USD | Delayed | |
0RC6 | London | EUR | Real-time | |
PMRA | Frankfurt | EUR | Delayed | |
PHMA | Vienna | EUR | Real-time |
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
Name | Age | Since | Title |
---|---|---|---|
Jose Maria Fernandez Sousa-Faro | - | 1986 | Founder, Executive Chairman, CEO & President |
Pedro Francisco Fernandez Puentes | - | - | Executive Vice-Chairman |
Rosa Maria Sanchez-Yebra Alonso | - | 2022 | Independent Director |
Montserrat Andrade Detrell | - | - | Proprietary Director |
Eduardo Serra Rexach | 76 | 2021 | Independent Other External Director |
M. Carlos Solchaga Catalan | 78 | - | Independent Other External Director |
Blanca Hernandez Rodriguez | - | 2019 | Independent Director |
Maria Sandra Ortega Mera | - | 2020 | Representative Proprietary Director |
Emiliano Calvo Aller | - | 2022 | Independent Director |
Fernando Martin-Delgado Santos | - | - | Independent Other External Director |
Soledad Cuenca Miranda | - | 2023 | Independent Director |
Mariano Esteban Rodriguez | - | 2022 | Independent Coordinating Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review